These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 30067248)

  • 1. Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
    Popovic A; Jaffee EM; Zaidi N
    J Clin Invest; 2018 Aug; 128(8):3209-3218. PubMed ID: 30067248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
    Collins JM; Redman JM; Gulley JL
    Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines.
    Faghfuri E
    Per Med; 2024 Jan; 21(1):45-57. PubMed ID: 38088165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.
    Heinhuis KM; Ros W; Kok M; Steeghs N; Beijnen JH; Schellens JHM
    Ann Oncol; 2019 Feb; 30(2):219-235. PubMed ID: 30608567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
    Gerber HP; Sapra P; Loganzo F; May C
    Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-Cell Therapy for Cancer.
    Yang JC; Rosenberg SA
    Adv Immunol; 2016; 130():279-94. PubMed ID: 26923004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of immunotherapy.
    Suzuki S; Ishida T; Yoshikawa K; Ueda R
    Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
    Esposito A; Criscitiello C; Curigliano G
    Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
    Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
    Kochin V; Nishikawa H
    Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tim-3 and its role in regulating anti-tumor immunity.
    Das M; Zhu C; Kuchroo VK
    Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antibodies targeting immune regulatory checkpoints for cancer therapy.
    Lee CS; Cragg M; Glennie M; Johnson P
    Br J Clin Pharmacol; 2013 Aug; 76(2):233-47. PubMed ID: 23701301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
    Yang W; Lee KW; Srivastava RM; Kuo F; Krishna C; Chowell D; Makarov V; Hoen D; Dalin MG; Wexler L; Ghossein R; Katabi N; Nadeem Z; Cohen MA; Tian SK; Robine N; Arora K; Geiger H; Agius P; Bouvier N; Huberman K; Vanness K; Havel JJ; Sims JS; Samstein RM; Mandal R; Tepe J; Ganly I; Ho AL; Riaz N; Wong RJ; Shukla N; Chan TA; Morris LGT
    Nat Med; 2019 May; 25(5):767-775. PubMed ID: 31011208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse Neoantigens and the Development of Cancer Therapies.
    Srivastava RM; Purohit TA; Chan TA
    Semin Radiat Oncol; 2020 Apr; 30(2):113-128. PubMed ID: 32381291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
    D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.